JP2025501766A5 - - Google Patents
Info
- Publication number
- JP2025501766A5 JP2025501766A5 JP2024538382A JP2024538382A JP2025501766A5 JP 2025501766 A5 JP2025501766 A5 JP 2025501766A5 JP 2024538382 A JP2024538382 A JP 2024538382A JP 2024538382 A JP2024538382 A JP 2024538382A JP 2025501766 A5 JP2025501766 A5 JP 2025501766A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- diseases
- disease
- cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904198A AU2021904198A0 (en) | 2021-12-22 | Bifunctional arylsulphonamide compounds | |
| AU2021904198 | 2021-12-22 | ||
| PCT/AU2022/051576 WO2023115150A1 (en) | 2021-12-22 | 2022-12-22 | Bifunctional arylsulphonamide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501766A JP2025501766A (ja) | 2025-01-23 |
| JP2025501766A5 true JP2025501766A5 (cg-RX-API-DMAC7.html) | 2025-12-22 |
Family
ID=86900830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538382A Pending JP2025501766A (ja) | 2021-12-22 | 2022-12-22 | 二官能性アリールスルホンアミド化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250115598A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4452978A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025501766A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240148322A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119032091A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022422212A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3241619A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007887A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023115150A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024007885A (es) * | 2021-12-22 | 2024-09-23 | Anaxis Pharma Pty Ltd | Compuestos de arilsulfonamida. |
| WO2024137742A1 (en) * | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
| WO2025051160A1 (zh) * | 2023-09-08 | 2025-03-13 | 北京华益健康药物研究中心 | 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815437A (en) * | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| WO2018192416A1 (en) * | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
| CN114521196A (zh) * | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| DK4168401T3 (da) * | 2020-06-19 | 2026-04-13 | Anaxis Pharma Pty Ltd | Sulfonamidforbindelser |
| MX2024007885A (es) * | 2021-12-22 | 2024-09-23 | Anaxis Pharma Pty Ltd | Compuestos de arilsulfonamida. |
-
2022
- 2022-12-22 EP EP22908912.3A patent/EP4452978A4/en active Pending
- 2022-12-22 CN CN202280091779.5A patent/CN119032091A/zh active Pending
- 2022-12-22 KR KR1020247024219A patent/KR20240148322A/ko active Pending
- 2022-12-22 US US18/722,099 patent/US20250115598A1/en active Pending
- 2022-12-22 WO PCT/AU2022/051576 patent/WO2023115150A1/en not_active Ceased
- 2022-12-22 CA CA3241619A patent/CA3241619A1/en active Pending
- 2022-12-22 MX MX2024007887A patent/MX2024007887A/es unknown
- 2022-12-22 AU AU2022422212A patent/AU2022422212A1/en active Pending
- 2022-12-22 JP JP2024538382A patent/JP2025501766A/ja active Pending